Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$294.18
-0.3%
$276.27
$190.75
▼
$302.93
$521.50B0.25.28 million shs4.71 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$271.73
-1.3%
$242.69
$188.08
▼
$282.15
$17.18B0.4694,460 shs870,226 shs
AstraZeneca Plc stock logo
AZN
AstraZeneca
$183.96
-0.3%
$169.24
$153.41
▼
$212.71
$285.96B0.243.10 million shs1.94 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$282.62
-1.1%
$267.12
$195.90
▼
$290.25
$682.52B0.227.47 million shs7.94 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$282.62
-1.1%
$267.12
$195.90
▼
$290.25
$682.52B0.227.47 million shs7.94 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.34%+0.45%+3.11%+13.58%+26.57%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-1.33%+4.57%+20.63%+9.19%+32.94%
AstraZeneca Plc stock logo
AZN
AstraZeneca
-0.38%-2.76%+11.34%+14.82%+3.23%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-1.10%+0.27%+10.60%+4.27%+44.19%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-1.10%+0.27%+10.60%+4.27%+44.19%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$294.18
-0.3%
$276.27
$190.75
▼
$302.93
$521.50B0.25.28 million shs4.71 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$271.73
-1.3%
$242.69
$188.08
▼
$282.15
$17.18B0.4694,460 shs870,226 shs
AstraZeneca Plc stock logo
AZN
AstraZeneca
$183.96
-0.3%
$169.24
$153.41
▼
$212.71
$285.96B0.243.10 million shs1.94 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$282.62
-1.1%
$267.12
$195.90
▼
$290.25
$682.52B0.227.47 million shs7.94 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$282.62
-1.1%
$267.12
$195.90
▼
$290.25
$682.52B0.227.47 million shs7.94 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.34%+0.45%+3.11%+13.58%+26.57%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-1.33%+4.57%+20.63%+9.19%+32.94%
AstraZeneca Plc stock logo
AZN
AstraZeneca
-0.38%-2.76%+11.34%+14.82%+3.23%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-1.10%+0.27%+10.60%+4.27%+44.19%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-1.10%+0.27%+10.60%+4.27%+44.19%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.83
Moderate Buy$297.851.24% Upside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2.90
Moderate Buy$314.1015.59% Upside
AstraZeneca Plc stock logo
AZN
AstraZeneca
2.84
Moderate Buy$206.6712.34% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.73
Moderate Buy$275.92-2.37% Downside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.73
Moderate Buy$275.92-2.37% Downside

Current Analyst Ratings Breakdown

Latest AZN, ABBV, JNJ, ASND, and JNJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetOverweight$325.00 ➝ $335.00
11/16/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetOverweight$329.00 ➝ $341.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UpgradeHold (C) ➝ Hold (C+)
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Set Price Target$352.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Reiterated RatingOutperform
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetOverweight$326.00 ➝ $330.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Set Price Target$330.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetBuy$269.00 ➝ $315.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Reiterated RatingOutperform$290.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetBuy$341.00 ➝ $352.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetHold$268.00 ➝ $274.00
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$66.01B7.88$15.13 per share19.44($2.57) per share-114.47
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.20B14.09N/AN/A($2.97) per share-91.49
AstraZeneca Plc stock logo
AZN
AstraZeneca
$58.74B4.86$12.90 per share14.26$33.41 per share5.51
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.19B7.22$14.07 per share20.08$33.87 per share8.34
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.19B7.22$14.07 per share20.08$33.87 per share8.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$5.8150.6318.361.3415.67%-450.55%16.50%2/3/2027 (Estimated)
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$15.3017.7630.23N/A73.26%44.80%14.23%N/A
AstraZeneca Plc stock logo
AZN
AstraZeneca
$10.23B$7.0718.2216.221.4317.68%31.85%13.62%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$6.6042.8224.452.8016.20%31.64%13.04%1/26/2027 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$6.6042.8224.452.8016.20%31.64%13.04%1/26/2027 (Estimated)

Latest AZN, ABBV, JNJ, ASND, and JNJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/31/2026Q3 2026
AstraZeneca Plc stock logo
AZN
AstraZeneca
$2.60$2.79+$0.19$2.00$16.00 billion$16.21 billion
10/30/2026Q3 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.73$3.82+$0.09$2.37$17.32 billion$17.40 billion
10/13/2026Q3 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.53$2.59+$0.06$0.09$25.38 billion$25.40 billion
10/13/2026Q3 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.53$2.59+$0.06$0.09$25.38 billion$25.40 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$7.282.47%+6.80%125.30%53 Years
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
AstraZeneca Plc stock logo
AZN
AstraZeneca
$2.171.18%+2.30%30.69%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.361.90%+5.25%81.21%64 Years
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.361.90%+5.25%81.21%64 Years

Latest AZN, ABBV, JNJ, ASND, and JNJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/29/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.822.47%1/15/20271/15/20272/16/2027
10/13/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.15%11/24/202611/24/202612/8/2026
10/13/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.15%11/24/202611/24/202612/8/2026
9/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.44%10/15/202610/15/202611/16/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.87
0.75
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
AstraZeneca Plc stock logo
AZN
AstraZeneca
0.51
1.01
0.79
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.44
1.02
0.74
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.44
1.02
0.74

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
AstraZeneca Plc stock logo
AZN
AstraZeneca
20.35%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
AstraZeneca Plc stock logo
AZN
AstraZeneca
N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
AstraZeneca Plc stock logo
AZN
AstraZeneca
96,1001.55 billionN/AOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.40 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.40 billionOptionable

Recent News About These Companies

J&J bets $2.2B on Ollin’s vision loss drug
Johnson & Johnson Stocks Edge Higher on $2.2 Billion Ollin Eye Deal
J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences
Sector Update: Healthcare Stocks Decline Late Afternoon
Johnson & Johnson (JNJ) Eyes Ollin Biosciences, Is It 19% Overvalued?
Johnson & Johnson Reportedly in Talks to Acquire Ollin Biosciences
Blackstone Life Sciences Announces $750 Million R&D Funding Agreement
Sector Update: Healthcare Stocks Advance Premarket Monday
J&J Stock Rallies More Than 10% in a Month: Time to Buy, Sell or Hold?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$294.18 -0.85 (-0.29%)
Closing price 11/16/2026 03:59 PM Eastern
Extended Trading
$294.62 +0.44 (+0.15%)
As of 04:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$271.73 -3.66 (-1.33%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$265.19 -6.54 (-2.41%)
As of 04:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

AstraZeneca stock logo

AstraZeneca NYSE:AZN

$183.96 -0.49 (-0.26%)
Closing price 11/16/2026 03:59 PM Eastern
Extended Trading
$183.43 -0.53 (-0.29%)
As of 04:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$282.62 -3.13 (-1.09%)
Closing price 11/16/2026 03:59 PM Eastern
Extended Trading
$281.98 -0.65 (-0.23%)
As of 05:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$282.62 -3.13 (-1.09%)
Closing price 11/16/2026 03:59 PM Eastern
Extended Trading
$281.98 -0.65 (-0.23%)
As of 05:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.